BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF), which is developing targeted cancer treatments, has delivered a second batch of preclinical data that underscores the potential of its lead drug candidate.
BVX001, which is designed to treat acute myeloid leukaemia (AML), uses the company's Bi-Cygni antibody-drug conjugate (ADC) to improve cancer cell selectivity and anti-cancer activity.
In recent tests, it proved highly effective in shrinking tumours in animal models. Notably, in a study involving larger-sized tumours (approximately 650mm3), BVX001 demonstrated a significant 89% tumour regression.
These findings, coming just weeks after similar promising results in a smaller tumour study, indicate the drug's effectiveness even in larger, tougher cases.
This is a considerable feat as many anti-cancer agents struggle with larger tumours due to reduced drug penetration.
These positive results bolster the potential of BVX001, advancing it closer to the clinical stage. Investors in biotech stocks will want to keep an eye on BiVictriX Therapeutics as they continue to make waves in the development of next-generation cancer treatments.
"The highly statistically significant tumour regression observed in large tumours treated with BVX001, from our second in vivo efficacy study, provides further evidence of our lead asset's potential for targeting patients with challenging-to-treat cancers," said BiVictriX chief executive, Tiffany Thorn.
"In a short space of time, we have built a comprehensive preclinical data package, with each new data set providing additional validation of our Bi-Cygni therapeutic approach, moving us one step closer to the clinic and offering additional options for future expansion into other indications.
"We are moving expeditiously to advance BVX001 into human trials and are laying the groundwork for future manufacturing, clinical and commercialisation activities."